Press Releases - Emmaus Medical, Inc.

FDA Approves Updated Label for Endari®November 03, 2020

Emmaus Life Sciences, Inc., announced today revised prescribing information for Endari® to better inform healthcare professionals and sickle cell disease patients.

Emmaus Life Sciences Announces Informational Stockholders MeetingSeptember 01, 2020

Emmaus announced today that it will hold an informational meeting of stockholders at which management will provide an update on recent sales activities and other business and operations.

Emmaus Life Sciences Announces Submission of Marketing Authorization Application to the Saudi Food and Drug AuthorityAugust 18, 2020

Emmaus announced today the submission of an application to the Saudi Food and Drug Authority (SFDA) for Marketing Authorization (MA) for Endari® in the Kingdom of Saudi Arabia.

Emmaus Life Sciences Reports Additional Positive Preliminary Results in Diverticulosis Pilot TrialAugust 05, 2020

Interim Analysis Indicates Decreased Number of Diverticula and Healthy Tissue

Emmaus Life Sciences Provides Additional Operational and OTC Markets UpdatesJuly 31, 2020

Emmaus provided today additional operational updates for the year ended December 31, 2019 as well as operational updates for the quarters ended March 31 and June 30, 2020